ClinicalTrials.gg
RecruitingNCT05740956Updated Jun 5, 2025

A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of HS-10502 in Ovarian Cancer, Breast Cancer and Pancreatic Cancer, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
318
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 393 studies in Ovarian Neoplasms with a site in China — 199 open to participants now, 231 under way, 36 of them phase 3. Ovarian Neoplasms · China.

Planned enrollment
59th of 320
318 · median 83
Started
2023
with 34 others
Phase 1
70 of 393
37 open now
Primary completion
2026-04
later than 72 of 230 live
Registered
199th of 393
by date

Among the 393 studies in Ovarian Neoplasms with a site in China, this one is the 59th largest by planned enrollment of the 320 interventional ones that give a count, is one of 35 that started in 2023, is one of 70 in phase 1, reaches primary completion later than 72 of the 230 other live ones, and was the 199th registered.

Ovarian Neoplasms

3,389 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

199 of the 393 studies in Ovarian Neoplasms with a site in China are open now. Recruiting first, the newest first:

194 more — sign in →

All 199 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 393 studies in Ovarian Neoplasms with a site in China, or all of them as a file.
02

Study summary

HS-10502 is a Poly(ADP-ribose) polymerase 1 (PARP1)-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 in subjects with homologous recombination repair (HRR) gene mutant or homologous recombination deficiency (HRD) positive advanced solid tumors.

03

Conditions studied

  • Ovarian Cancer
  • Breast Cancer
  • Pancreatic Cancer
  • Prostatic Cancer
  • Colorectal Cancer

Keywords

  • Poly(ADP-ribose) polymerase-1 inhibitor
  • HS-10502
  • Ovarian Cancer
  • Breast Cancer
  • Prostate Cancer, Colorectal Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females aged 18 - 75 years (inclusive).
  2. Having at least one target lesion per the v1.1.
  3. For the phase Ia Cohort A: advanced solid tumor carrying HRR gene mutation with failure or intolerance or not available to the currently available Standard of care (SoC).
  4. For the phase Ib study:

    Cohort B: patients with HRD positive recurrent ovarian cancer with failure or intolerance or not available to SoC Cohort C: patients with HRR gene mutation advanced Human epidermal growth factor receptor 2 ()-negative breast cancer with failure or intolerance or not available to SoC Cohort D: patients with HRR gene mutation advanced pancreatic cancer with failure or intolerance or not available to SoC Cohort E: patients with HRR gene mutation mCRPC with failure or intolerance or not available to SoC Cohort F: patients with HRR gene mutation colorectal cancer with failure or intolerance or not available to SoC Cohort G: patients with other HRR gene mutation or HRD positive advanced solid tumors with failure or intolerance or not available to SoC

  5. (ECOG) performance status was 0-1.
  6. Minimum > 12 weeks.
  7. Females should be using adequate measures and should not be breastfeeding Males should be using adequate contraceptive measures.
  8. Have signed Form.

Exclusion criteria

Exclusion Criteria:

  1. Received or are receiving the following treatments:

    1. Previous or current treatment with two or more Poly(ADP-ribose) polymerase (PARP) inhibitors.
    2. Traditional Chinese medicine indicated for tumors within 2 weeks prior to the first dose of study treatment.
    3. Cytotoxic chemotherapeutic drugs, drugs or other systematic anti-tumor therapies within 3 weeks before the first dose of study treatment; Nitrosourea or Mitomycin C within 6 weeks prior to the first dose of study treatment.
    4. Local radiotherapy within 2 weeks prior to the first dose of study treatment; more than 30% of bone marrow radiotherapy or large-area irradiation within 4 weeks before the first dose of study treatment.
    5. Presence of pleural effusion/ascites requiring clinical intervention; presence of pericardial effusion.
    6. Major surgery within 4 weeks prior to the first dose of study treatment.
  2. Presence of Grade ≥ 2 toxicities due to prior anti-tumor therapy.
  3. History of other primary .
  4. Known and untreated, or active central nervous system .
  5. Inadequate bone marrow reserve or hepatic and renal functions.
  6. Myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML), or with features suggestive of MDS or AML.
  7. Severe, uncontrolled or active cardiovascular disorders.
  8. Diabetic ketoacidosis or hyperosmolar hyperglycemic state within 6 months prior to the first dose of study treatment; glycosylated ≥ 7.5%.
  9. Serious or poorly controlled hypertension.
  10. Any life-threatening hemorrhagic event or events requiring blood transfusion within 120 days prior to the first dose of study treatment. hemorrhagic symptoms or obvious hemorrhagic tendency.
  11. Serious infection within 4 weeks prior to the first dose of study treatment, or presence of uncontrollable active infection in the screening period.
  12. Having serious neurological or mental disorders.
  13. A history of to any of the active or inactive ingredients of HS-10502 or drugs with a similar chemical structure to HS-10502 or in the same class as HS-10502.
  14. Patients who may have poor compliance with the procedures and requirements of the study, as judged by the investigator.
  15. Patients with any condition that jeopardizes the safety of the patient or interferes with the assessment of the study, as judged by the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
318 participants (estimated)

Study arms

  • Experimental
    HS-10502

    HS-10502 Tablets,PO,QD

    Drug: HS-10502

Interventions

  • DrugHS-10502

    HS-10502 will be administered once per day on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28-day treatment cycle.

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) of HS-10502(Stage 1)

    MTD is defined as the previous dose level at which 2 or more out of 2-6 subjects experienced a Dose-limiting toxicity (DLT)

    Time frame: Cycle 1 (28 days)

  2. Maximum applicable dose (MAD) of HS-10502(Stage 1)

    MAD is defined as follows: a) based on PK data, it is anticipated that at this dose level, the dose-exposure plateau has been reached, b) based on existing safety data, it is judged that dose escalation following this dose level will have a large safety risk or subject intolerance, or c) based on the pharmacokinetics-pharmacodynamics (PK-PD) model, it suggested that the optimal target concentration of safety and efficacy has been explored

    Time frame: Cycle 1 (28 days)

  3. Efficacy of HS-10502: Objective response rate (ORR)(Stage 2)

    ORR is defined as the proportion of participants with Best Overall Response (BOR) of confirmed CR or confirmed PR per RECIST v1.1 (applicable for all solid tumors except prostate cancer) or per RECIST v1.1 and PCWG3 (for prostate cancer only)

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years

Secondary outcomes

  1. [Stage 1 and Stage 2] Incidence and severity of treatment-emergent adverse events

    Assessed by number and severity of adverse events as evaluated according to NCI CTCAE v5.0.

    Time frame: From Cycle 1 Day 1 (C1D1) until 28 days after the final dose. A cycle is 28 days

  2. [Stage 1 and Stage 2] PK parameters: The maximum observed concentration (Cmax) of HS-10502

    Maximum plasma drug concentration of HS-10502

    Time frame: Cycle 1 Day 1 (each cycle is 28 days)

  3. [Stage 1 and Stage 2] PK parameters: time to Cmax (Tmax) of HS-10502

    Time of maximum observed concentration of HS-10502

    Time frame: Cycle 1 Day 1 (each cycle is 28 days)

  4. [Stage 1 and Stage 2] PK parameters: area under the concentration-time curve from time 0 to time t of last measurable concentration (AUC0-t) of HS-10502

    Area under the curve from the time of dosing to the time of the last measurable (positive) concentration

    Time frame: Cycle 1 Day 1 (each cycle is 28 days)

  5. [Stage 1 and Stage 2] PK parameters: Maximum plasma concentration at steady state (Css, max) of HS-10502

    Maximum plasma drug concentration at steady state of HS-10502.

    Time frame: Cycle 2 Day 1 (each cycle is 28 days)

  6. [Stage 1 and Stage 2] PK parameters: time to Css, max (Tss, max) of HS-10502

    Time of maximum observed concentration at steady state of HS-10502

    Time frame: Cycle 2 Day 1 (each cycle is 28 days)

  7. [Stage 1 and Stage 2] PK parameters: Minimum plasma concentration at steady state (Css, min) of HS-10502

    Minimum plasma drug concentration at steady state of HS-10502

    Time frame: Cycle 2 Day 1 (each cycle is 28 days)

  8. [Stage 1 and Stage 2] PK parameters: Area under the plasma concentration-time curve over a dosing interval at steady state (AUCss) of HS-10502

    The partial area from dosing time to dosing time plus dosing interval of HS-10502

    Time frame: Cycle 2 Day 1 (each cycle is 28 days)

  9. Efficacy of HS-10502: ORR

    Proportion of participants with BOR of confirmed CR or confirmed Partial Response (PR) per RECIST v1.1 (applicable for all solid tumors except prostate cancer) or per RECIST v1.1 and The prostate cancer working group 3 criteria (PCWG3) (for prostate cancer only)

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years

  10. [Stage 1 and Stage 2] Efficacy of HS-10502: disease control rate (DCR)

    P Percentage of patients who have a best overall response (confirmed CR, PR, or stable disease for at least 5 weeks) per RECIST v1.1 (applicable for all solid tumors except prostate cancer) or per RECIST v1.1 and PCWG3 (for prostate cancer only)

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years

  11. Title: [Stage 1 and Stage 2] Efficacy of HS-10502: duration of response (DoR)

    DoR only applies to participants whose best overall response is CR or PR based on assessment per RECIST v1.1 (applicable for all solid tumors except prostate cancer) or per RECIST v1.1 and PCWG3 (for prostate cancer only). The start date is the date of first documented response of CR or PR (i.e. the start date of observed response, not the date when response was confirmed), and the end date is the date of the first documented progression or death due to underlying cancer.

    Time frame: From the date of CR, PR until the date of disease progression or withdrawal from study, approximately 2 years

  12. [Stage 1 and Stage 2] Efficacy of HS-10502: progression free survival (PFS) (applicable for all solid tumors except prostate cancer)

    Time from the date of randomization or first dose (if randomization is not needed) to the date of the first documented progression or death due to any cause. PFS will be assessed per RECIST v1.1.

    Time frame: From the date of randomization or first dose (if randomization is not needed) until the date of disease progression or withdrawal from study, approximately 2 years.

  13. [Stage 1 and Stage 2] Efficacy of HS-10502: radiographic progression free survival (rPFS) (for prostate cancer only)

    Time from the date of randomization or first dose (if randomization is not needed) to the date of the first documented progression or death due to any cause. rPFS will be assessed per RECIST v1.1 (soft tissue) and PCWG3 (bone).

    Time frame: From the date of randomization or first dose (if randomization is not needed) until the date of disease progression or withdrawal from study, approximately 2 years

  14. [Stage 1 and Stage 2] Efficacy of HS-10502: ORR evaluated by RECIST v1.1 and Gynecologic Cancer Intergroup (GCIG) CA-125 (for ovarian cancer only)

    Proportion of participants with BOR of confirmed CR or confirmed PR per both RECIST v1.1 and GCIG CA-125 criteria.

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years

  15. [Stage 2] Efficacy of HS-10502: overall survival (OS)

    Time from the date of randomization or first dose (if randomization is not needed) to the date of death due to any cause. For each participant who is not known to have died as of the cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive

    Time frame: From the date of randomization or first dose (if randomization is not needed) until the documentation of death from any cause, approximately 4 years

  16. [Stage 1 and Stage 2] Efficacy of HS-10502: Proportion of subjects with Carbohydrate antigen (CA)-125 decreased by ≥ 50% from baseline (for ovarian cancer only)

    The percentage of subjects (ovarian cancer only) with a reduction of at least 50% from baseline in CA-125 levels.

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years

  17. [Stage 1 and Stage 2] Efficacy of HS-10502: ≥ 50% PSA decrease (PSA50) response rate (for prostate cancer only)

    Proportion of subjects with a Prostate-specific antigen (PSA) nadir of ≤ 50% of baseline PSA level confirmed by serial PSA assessments (at least 3 weeks apart) after the start of the study.

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years

  18. [Stage 1 and Stage 2] Efficacy of HS-10502: Time to PSA progression (for prostate cancer only)

    Time from the first dose to PSA progression based on PCWG3 criteria.

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years

07

Study locations

1 of 1 sites recruiting
  • Cancer Hospital Chinese Acedemy of Medical Sciences
    Beijing, Beijing 100020, China
    Recruiting
    • Da Wei Wu · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Apr 2026, 33 months after the start.

Of 210 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 33 months is below that.

Counting every sponsor, half of 380 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2023
First posted
Feb 23, 2023
StartActual
Jun 9, 2023
Primary completionEst.
Apr 1, 2026
CompletionEst.
Oct 1, 2026
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05740956
Responsible party
Sponsor
First posted
Feb 23, 2023
Start date
Jun 9, 2023
Primary completion
Apr 1, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Jun 5, 2025

Study contacts

Lingying Wu, Medical PhD
Contact
wulingying@csco.org.cn
13910865483

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion